GBT (Global Blood Therapeutics) Competitors and Similar CompaniesClear all

GBT (Global Blood Therapeutics)'s competitors and similar companies include Acceleron Pharma, CalciMedica, Immunicum and Marinomed.

	GBT (Global Blood Therapeutics) GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need.	Acceleron Pharma Acceleron Pharma is a clinical-stage biopharmaceutical company.	CalciMedica CalciMedica (formerly known as Graybug Vision) is a biotechnology company that develops calcium release-activated calcium (CRAC) channel inhibitors.	Immunicum Immunicum is a biopharmaceutical company that develops immune therapies against a range of various tumors.	Marinomed Marinomed Biotech is a biopharmaceutical company.
Founding Date	Founding Date 2012	Founding Date 2003	Founding Date 2007	Founding Date 2002	Founding Date 2006
Type	Type Public	Type Subsidiary	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy
Locations	Locations South San Francisco, US HQ Paris, FR Berlin, DE Baar, CH London, GB	Locations Cambridge, US HQ Zug, CH	Locations La Jolla, US HQ	Locations Stockholm, SE HQ Leiden, NL	Locations Korneuburg, AT HQ
Employees	Employees 352106% increase	Employees 636% decrease	Employees 1614% increase	Employees 28	Employees 31
Valuation ($)	Valuation ($) 4.4 b	Valuation ($) N/A	Valuation ($) 42.4 m	Valuation ($) 49.3 m	Valuation ($) 14.3 m
Financial
Revenue (est.)	Revenue (est.) $194.7m (FY, 2021)	Revenue (est.) $92.5m (FY, 2020)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods $3.3m (FY, 2021)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A
Net income	Net income ($303.1m) (FY, 2021)	Net income ($166m) (FY, 2020)	Net income ($29.6m) (FY, 2025)	Net income (kr113.3m) (FY, 2025)	Net income N/A
Funding
Total funding raised	Total funding raised $ 88.7m	Total funding raised $ 141.8m	Total funding raised $ 74.5m	Total funding raised N/A	Total funding raised $ 1.6m